Conventional vs Biologic Therapy in Pediatric IBD

September 8, 2026 updated by: Elizabeth Makar Ishak, Assiut University

Effectiveness, Safety, and Adverse Events of Conventional and Biologic Therapy in Pediatric Inflammatory Bowel Disease

This combined retrospective-prospective cohort study aims to evaluate the effectiveness, safety, and adverse events of conventional versus biologic therapy in children and adolescents with inflammatory bowel disease at Assiut University Children Hospital.

Study Overview

Status

Not yet recruiting

Detailed Description

Pediatric-onset inflammatory bowel disease differs from adult-onset disease in phenotype, disease extent, and long-term prognosis. Conventional therapy (5-aminosalicylates, corticosteroids, and immunomodulators) and biologic therapy (mainly anti-TNFα agents) are used for induction and maintenance of remission.

This observational cohort study will include pediatric patients with confirmed Crohn's disease, ulcerative colitis, or IBD-unclassified. Patients will be classified into conventional therapy and biologic therapy groups. Clinical remission, response rates, steroid-free remission, adverse events, and growth parameters will be assessed over a 12-month period.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Children and adolescents up to 18 years of age with confirmed inflammatory bowel disease receiving conventional and/or biologic therapy at Assiut University Children Hospital and the Health Insurance IBD Committee, Assiut Branch.

Description

Inclusion Criteria:

  • - Confirmed diagnosis of Crohn's disease, ulcerative colitis, or IBD-unclassified according to revised Porto criteria
  • Age at diagnosis less than 18 years
  • Receipt of conventional therapy and/or biologic therapy for a minimum evaluable treatment duration
  • Availability of adequate medical records
  • Written informed consent (for prospective component)

Exclusion Criteria:

  • - Incomplete medical records precluding assessment of primary endpoints
  • Age more than 18 years
  • Discontinuation of follow-up before a minimum evaluable treatment period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Conventional Therapy
Patients managed with 5-aminosalicylates, corticosteroids, and/or immunomodulators without biologic exposure during the observation period.
Biologic Therapy
Patients who received biologic therapy (with or without concomitant conventional agents) during the observation period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical remission rate
Time Frame: At week 8-12, 6 months, and 12 months
Proportion of patients achieving clinical remission at week 8-12, 6 months, and 12 months, defined as PCDAI ≤ 10 for Crohn's disease or PUCAI < 10 for ulcerative colitis.
At week 8-12, 6 months, and 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical response rate
Time Frame: At week 8-12, 6 months, and 12 months
Proportion of patients achieving clinical response, defined as a decrease from baseline of ≥12.5 points in PCDAI (Crohn's disease) or ≥20 points in PUCAI (ulcerative colitis).
At week 8-12, 6 months, and 12 months
Steroid-free remission rate
Time Frame: At 12 months
Proportion of patients in clinical remission without systemic corticosteroid use.
At 12 months
Incidence of adverse events
Time Frame: Through 12 months
Proportion of patients experiencing adverse events (infusion/injection reactions, infections, hematologic abnormalities, hepatotoxicity), graded according to CTCAE-adapted criteria
Through 12 months
Change in growth parameters
Time Frame: From baseline to 12 months
Change in height z-score, weight z-score, and BMI z-score from baseline.
From baseline to 12 months
Treatment escalation or switch rate
Time Frame: Through 12 months
Proportion of patients requiring treatment escalation or switching between conventional and biologic agents.
Through 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Nafisa H Abdel-Aziz, prof, pediatrics Department, Assiut University Hospitals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 10, 2026

Primary Completion (Estimated)

September 10, 2027

Study Completion (Estimated)

January 10, 2028

Study Registration Dates

First Submitted

September 8, 2026

First Submitted That Met QC Criteria

September 8, 2026

First Posted (Actual)

September 14, 2026

Study Record Updates

Last Update Posted (Actual)

September 14, 2026

Last Update Submitted That Met QC Criteria

September 8, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe